Modality
Bispecific Ab
MOA
Anti-Aβ
Target
JAK2
Pathway
Angiogenesis
Melanoma
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Apr 2027
Phase 2Current
NCT06567396
2,597 pts·Melanoma
2018-12→TBD·Terminated
NCT05004941
169 pts·Melanoma
2021-12→2027-04·Not yet recruiting
2,766 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-121.0y awayPh3 Readout· Melanoma
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Termina…
P2/3
Not yet…
Catalysts
Ph3 Readout
2027-04-12 · 1.0y away
Melanoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06567396 | Phase 2/3 | Melanoma | Terminated | 2597 | HAM-D |
| NCT05004941 | Phase 2/3 | Melanoma | Not yet recr... | 169 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 |